Clinical Trial Detail

NCT ID NCT02752035
Title A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Astellas Pharma Global Development, Inc.
Indications

acute myeloid leukemia

Therapies

Gilteritinib

Azacitidine + Gilteritinib

Azacitidine

Age Groups: senior adult

Additional content available in CKB BOOST